Berndt Modig, Pharvaris CEO
August 22, 2022 11:16 AM EDTUpdated August 23, 01:46 PM
FDA+

Phar­varis hits a snag with hered­i­tary an­gioede­ma pill as FDA places hold on tri­als

Aayushi Pratap

News Reporter

Swiss biotech Phar­varis an­nounced Mon­day that the FDA has placed a hold on the clin­i­cal tri­als for its oral drug PHA121 which aims at treat­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times